Iambic Therapeutics Inc.
IAMHealthcare|Biotechnology|US
$10.17
-1.47 (-12.63%)
About
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Stock Price
-40.1%(1Y)
1M
-40.1%
3M
-40.1%
6M
-40.1%
YTD
-40.1%
1Y
-40.1%
3Y
-40.1%
5Y
-40.1%
Pipeline Summary
1 total trials1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors
Phase 1Recruiting
Enrollment: 383 participants
Key Facts
Market Cap$95.3M
Employees171
CEOThomas Miller
IPO DateOct 15, 2026
Beta0.00
52-Week Range$9.6 – $25
Avg Volume824,485
ExchangeNASDAQ
Websiteiambic.ai
Ownership
Shares Outstanding9.4M
Recent Insider Trades
Catalio Capital Management, LPCONVERSION
Oct 16, 20261,995,749 shares
Catalio Capital Management, LPCONVERSION
Oct 16, 20261,458,290 shares
Catalio Capital Management, LPCONVERSION
Oct 16, 2026742,546 shares @ $16.00
Catalio Capital Management, LPCONVERSION
Oct 16, 20261,141,878 shares
Catalio Capital Management, LPCONVERSION
Oct 16, 2026731,187 shares
Recent News
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Oct 26, 2026 · businesswire.com
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
Oct 17, 2026 · seekingalpha.com
Iambic Announces Pricing of Initial Public Offering
Oct 14, 2026 · businesswire.com
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
Oct 8, 2026 · reuters.com
Data last updated: Nov 9, 2026, 04:14 AM